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Influenza vaccination programmes are assumed to 
have a herd effect and protect contacts of vaccinated 
persons from influenza virus infection. We searched 
MEDLINE, EMBASE, the Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Global Health 
and the Cochrane Central Register of Controlled Trials 
(CENTRAL) from inception to March 2014 for studies 
assessing the protective effect of influenza vaccina-
tion vs no vaccination on influenza virus infections 
in contacts. We calculated odds ratios (ORs) and 95% 
confidence intervals (CIs) using a random-effects 
model. Of 43,082 screened articles, nine randomised 
controlled trials (RCTs) and four observational studies 
were eligible. Among the RCTs, no statistically sig-
nificant herd effect on the occurrence of influenza in 
contacts could be found (OR: 0.62; 95% CI: 0.34–1.12). 
The one RCT conducted in a community setting, how-
ever, showed a significant effect (OR: 0.39; 95% CI: 
0.26–0.57), as did the observational studies (OR: 0.57; 
95% CI: 0.43–0.77). We found only a few studies that 
quantified the herd effect of vaccination, all studies 
except one were conducted in children, and the overall 
evidence was graded as low. The evidence is too lim-
ited to conclude in what setting(s) a herd effect may or 
may not be achieved.
Introduction
Influenza is a major cause of morbidity and mortality 
worldwide [1-3]. Many countries recommend vaccina-
tion against influenza to prevent influenza infections, 
in particular for groups at high risk for complications 
[4-7]. Some high risk groups, such as young children 
and elderly persons (commonly defined as those above 
65 years of age), experience decreased influenza vac-
cine effectiveness compared with healthy adults 
[8,9], complicating influenza prevention strategies. 
Moreover, because such groups represent a minority of 
the population at large, the population-wide impact of 
vaccination of risk groups may be limited [7,10].
Influenza vaccine modelling and ecological studies 
identifying benefits of herd effect have informed sea-
sonal and pandemic influenza vaccine policies [10,11], 
herd effect being usually defined as the indirect protec-
tion of individuals susceptible to infection when a suf-
ficient proportion of the population is immune to the 
pathogen. Vaccinating persons most likely to respond 
to the influenza vaccine and relying on herd effect to 
reduce the chance of exposure to influenza may protect 
unvaccinated or high-risk individuals. Herd effect may 
therefore mitigate the consequences of impaired vac-
cine response in some high-risk groups [12-14].
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The purpose of this systematic review was to summa-
rise the evidence on herd effect from influenza vaccina-
tion outside healthcare settings. These data may help 
to inform public health on influenza vaccine research 
and policy development.
Methods
All decisions regarding eligibility criteria, search strat-
egy, study selection, assessment of risk for bias, 
explanation for heterogeneity, data collection and 
analysis were established before data collection. The 
protocol was registered with the international prospec-
tive register of systematic reviews (PROSPERO) [15] 
Figure 1
Flowchart of included and excluded randomised control trials and observational studies identified in a systematic review of 
herd effect from influenza vaccination in non-healthcare settings
EMBASE n = 25,578   
MEDLINE n = 19,536  
GLOBAL HEALTH n =  7,932
CINAHL n =  7,980
CENTRAL n =  213
Additional records identified through other sources
From bibliographies of relevant studies and review articles
n = 7
Number of records screened after duplicates (n = 18,157) removed
n = 43,082
Records identified through database searching
Number of records excluded 
based on screening of 
titles and abstracts
n = 42,898
Number of records meeting eligibility 
criteria for full text screening
n = 184
Studies excluded in full-text screening/data collection
Language other than English n = 12
n = 23
n = 13
n = 32
n = 14
n = 73
n = 4
n = 171
No original data provided
Ecological design
Intervention or comparator not eligible
Healthcare setting
No outcome of interest
Other reasons for exclusion
Number of articles excluded
Randomised controlled trials
Number of articles included with data collected
n = 9
Observational studies
Number of articles included with data collected
n = 4
Randomised controlled trials
Number of articles included in meta-analysis
n = 7
Observational studies
Number of articles included in meta-analysis
n = 4
a Two randomised control trials did not report all numerator and denominator data and therefore could not be included in the meta-analysis.
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(CRD42014009401) and was reported in accordance 
with the PRISMA statement [16].
Eligibility criteria and outcomes assessed
Studies assessing the protective effect of influenza 
vaccination vs no influenza vaccination (either no vac-
cination, placebo or alternative vaccine) on contacts of 
any age group in a non-healthcare setting were eligi-
ble. The definition of contacts was broad and included 
anyone in the same community, school or household. 
Study designs included randomised controlled trials 
(RCTs) and observational studies with a non-influenza 
vaccine comparator group. For the latter study type, 
quasi-experimental (before–after) studies, cohort 
studies, case–control studies and cross-sectional 
studies were eligible. Ecological studies and modelling 
studies were excluded. We also excluded studies con-
ducted within healthcare institutions, such as nursing 
homes and hospitals, and studies in languages other 
than English.
The primary outcome was influenza in non-vaccinated 
contacts exposed to persons vaccinated against influ-
enza vs those not vaccinated. Influenza included both 
laboratory-confirmed influenza (defined by one or 
more of the following: nucleic acid amplification test-
ing, viral culture, antigen detection, pre-/post-season 
or acute/convalescent serology) or non-laboratory-
defined evidence. Non-laboratory-defined evidence 
required the presence of influenza-like illness (ILI, as 
per the study definition) within a period of time when 
laboratory-confirmed influenza was circulating in the 
study area. Secondary outcomes included hospitalisa-
tion, pneumonia and death.
Search strategy, study selection and data 
extraction
We searched MEDLINE (since 1950), EMBASE (since 
1980), the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) (since 1982), Global Health 
(since 1973) and the Cochrane Central Register of 
Controlled Trials (CENTRAL) up to 7 March 2014. We 
also searched reference lists of identified articles and 
those of review articles for eligible studies.
Multiple teams of two reviewers independently 
screened titles and abstracts and, for studies identi-
fied by at least one reviewer to be of potential inter-
est, full-text articles were screened. Data from eligible 
studies were extracted independently by two review-
ers using a database. Any disagreement between the 
reviewers was resolved by consensus or arbitration by 
a third reviewer. We attempted to contact the first and 
corresponding author of the original article whenever 
potentially important information was missing.
Assessment of the risk of bias and of the overall qual-
ity of evidence was also conducted by two review-
ers independently. We used the Cochrane Review 
Collaboration’s tool [17] to assess the risk of bias for 
RCTs, and the Newcastle-Ottawa scale (NOS) [18] to 
assess the quality of observational studies. The over-
all quality of evidence was assessed using the grading 
of recommendations assessment, development and 
Figure 2
Meta-analysis of seven included randomised controlled trials reporting on influenza infections in contacts of influenza 
vaccinated vs unvaccinated individuals in non-healthcare settings
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evaluation (GRADE) criteria [19]. Given the small num-
ber of studies, no formal assessment of the risk of pub-
lication bias could be conducted [20].
Data analysis
We performed meta-analyses of RCTs and observa-
tional studies separately. We calculated odds ratios 
(ORs) and corresponding 95% confidence intervals 
(CIs) as summary estimates using random-effects mod-
elling (using RevMan 5.3 [21]).
We planned a priori to conduct two subgroup analyses. 
First, we examined herd effect by study setting, com-
paring the effect in household studies, school-based 
studies (where the impact on non-vaccinated school-
children was measured) and community studies. For 
community studies, those comparing geographically 
defined areas with different vaccination strategies 
were considered. We hypothesised that the closer the 
contact was to vaccinated persons, the stronger the 
effect would be. Second, we assessed whether the 
herd effect of the vaccination in young children (up to 
5 years of age) was different from that in older children 
and teenagers (5–18 years), and in adults.
Heterogeneity was evaluated using χ2 and I2 statis-
tics [22]. We considered a χ2 of < 0.10 or an I2 statistic 
of > 50% to reflect significant heterogeneity. If signifi-
cant heterogeneity was found, we planned to perform 
additional subgroup analyses. Our a priori hypotheses 
to explain heterogeneity beyond the planned subgroup 
analyses were: laboratory-confirmed vs non-labora-
tory-confirmed influenza cases, and cases confirmed 
by nucleic acid amplification testing and viral culture 
vs cases confirmed by other laboratory methods. We 
also analysed the predominant circulating type/sub-
type (influenza A(H3N2) orA(H1N1), and influenza B).
Results
After removing 18,157 duplicates, we screened a total 
of 43,082 titles and abstracts, reviewed 184 full-text 
articles and included nine RCTs and four observational 
studies in our systematic review (Figure 1). Of the 13 
RCTs and observational studies, seven were conducted 
in North America, and two each in Italy and Russia, and 
one in Malaysia and Hong Kong Special Administrative 
Region, respectively (Table 1).
Findings from randomised controlled trials
Of the nine RCTs included, seven were conducted in a 
household setting, one in a school and one in a com-
munity setting (Table 1). The intervention group con-
sisted of children in all but one study. The total sample 
Figure 3
Meta-analysis of four included observational studies reporting on influenza infections in contacts of influenza vaccinated vs 
unvaccinated patients in non-healthcare settings
s
c
c
p
p
p
t
t c p
p
p
( (
r r
( –
–
–
–
–
–
–
–
–
(
(
c p
p
t
(
( (
( (
( (
( (
( (
( (
( (
CI: confidence interval; df: degrees of freedom; M-H: Mantel-Haenszel.
5www.eurosurveillance.org
size of contacts was 4,975, with one study –the larg-
est– not reporting the total number of contacts [23].
A total of six RCTs provided data for the primary analy-
sis comparing influenza-like illness in contacts of vac-
cinated vs unvaccinated persons (Figure 2). Overall, 
no statistically significant herd effect was found (OR: 
0.62; 95% CI: 0.34–1.12), with significant statistical 
heterogeneity (I2 = 78%). Only one study, by Loeb et 
al., assessed contacts for influenza virus infection at 
community level: vaccination of children reduced the 
influenza infection rate for the community (OR: 0.39; 
95% CI: 0.26–0.57) [12]. In contrast, there was no 
statistically significant effect in the subgroup of RCTs 
assessing household contacts (OR: 0.71; 95% CI: 0.34–
1.50). No other differences between subgroups were 
found (p = 0.15 for subgroup differences). There was 
an 86% reduction in the odds of 5–17 year-old contacts 
of vaccinated individuals becoming infected as com-
pared with contacts of unvaccinated individuals (OR: 
0.14; 95% CI: 0.03–0.70), while no statistically signifi-
cant differences were found when contacts were less 
than five years-old or adults. This difference across age 
groups was not statistically significant (p = 0.26).
Given the significant amount of statistical heterogene-
ity in the primary analyses, we conducted additional 
subgroup analyses. Subgrouping by whether or not 
influenza was laboratory confirmed did not signifi-
cantly reduce statistical heterogeneity (p for subgroup 
differences was 0.06; I2 = 70·8%), with a significant 
effect on influenza infections in contacts in RCTs 
with no laboratory confirmation (OR: 0.33; 95% CI: 
0.17–0.64; I2 = 43%; n = 2) and no effect in RCTs using 
laboratory confirmation (OR: 0.87; 95% CI: 0.40–1.89; 
I2 = 81%; n = 4). Subgrouping by type of laboratory con-
firmation or by influenza virus type/subtype could not 
further explain the statistical heterogeneity.
Two RCTs provided data on hospitalisation of contacts, 
with no statistically significant difference seen (OR 
0.83; 95% CI: 0.17–4.1). Only the RCT by Loeb et al. [12] 
reported on mortality and pneumonia in contacts, with 
no effect of the vaccine on either of these outcomes in 
Table 1
Study characteristics of studies included in a systematic review of herd effect arising from influenza vaccination in non-
healthcare settings
First 
author 
[source]
Study 
location
Study 
period
Predominant 
influenza 
virus type or 
subtype Intervention group Setting
Number of 
vaccinees
Number of 
contactsa
Laboratory 
confirmation of 
influenza
Randomised control trials
Gruber [29] United States 1985/86 B Children aged 3–18 years Household 133 123 Yes
Clover [33] United States 1986/87 A(H1N1) Children aged 3–19 years Household 194 177 Yes
Rudenkob 
[23] Russia 1989–91 A(H3N2) Children aged 7–14 years School 11,071
Not 
available No
Hurwitz 
[13] United States 1996/97 Influenza B Children aged 2–5 years Household 127 228 No
Esposito 
[34] Italy 2000/01 H1N1
Children aged 0.5–9 
years Household 127 349 No
Principib 
[24] Italy 2001/02 Influenza B
Children aged 0.5–5 
years Household 303 1,098 No
Hui [31] Malaysia 2005 Not reported Adults aged 18–64 years Household 346 362 No
Cowling 
[30]
Hong Kong 
SAR 2008/09 A(H3N2) Children aged 6–15 years Household 119 312 Yes
Loeb [12] Canada 2009 A(H3N2) Children aged 1.5–15 years Community 947 2,326 Yes
Observational studies (all cohort studies)
Piedra [26] United States 1998–2001 A(H3N2)
Children aged 1.5–18 
years Community ca 40,000 350,296 No
Ghendon 
[25] Russia 2001–03 A(H3N2) Children aged 3–17 years Community 87,221 158,451 No
King [14] United States 2004/05 A(H3N2) Children aged 5–14 years Household 2,717 3,022c No
Kjos [27] United States 2010/11 A(H3N2) Children, age unavailable
Elementary 
school 
(5–10 year-olds)
1,012 937 No
  SAR: Special Administrative Region.
a The definition of contacts was broad and included anyone in the same community, school or household.
b The randomised control trial did not report all numerator and denominator data and therefore could not be included in the meta-analysis.
c In this study, the number of contacts was not reported. The number shown is the number of households (3,022) included in the analysis in 
intervention schools; there were 5,488 households in control schools). 
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community contacts. Because of the limited number of 
studies reporting these outcomes, no subgroup analy-
ses could be performed.
Two other RCTs demonstrated a herd effect of influ-
enza vaccination, but the data provided in the publica-
tions did not report the numerators and denominators 
needed for our meta-analysis, and we were unable to 
obtain further data or information from the authors. 
Principi et al. concluded that influenza vaccination 
significantly reduced the direct and indirect influenza-
related costs in healthy children and their unvaccinated 
family members [24]. Rudenko et al. found that the use 
of a live attenuated influenza vaccine was associated 
with a lower rate of influenza-like illness in school staff 
and non-vaccinated children when comparing schools 
that had vs schools that did not have an institutional 
influenza vaccination programme [23].
Findings from observational studies
A total of four observational studies were identified 
(Table 1). The intervention groups consisted of chil-
dren in all the studies. Two studies were conducted in 
a community setting, and one each in the household 
and school setting. The total sample size of contacts 
was more than 500,000. The level of analysis was the 
household, and not the individual person, in one of the 
studies [14].
Meta-analysis showed a significant reduction of influ-
enza illness in contacts of vaccinated patients (OR 
0.57; 95% CI: 0.43–0.77) (Figure 3). Heterogeneity 
was very high (I2 = 98%); however, the direction of the 
effect was identical in all studies, only the amount of 
the effect size varied across studies. No age-specific 
data were available. When comparing the three study 
settings, no significant subgroup effect was found (p 
= 0.85 for subgroup differences). Given that all studies 
were lacking laboratory confirmation, and all were con-
ducted during influenza A(H3N2)-predominant influ-
enza seasons, no further subgroup analyses could be 
performed.
Only Ghendon et al. [25] reported on pneumonia, and 
found a significant reduction in contacts of influenza 
vaccinated patients (OR: 0.38; 95% CI: 0.30–0.50). 
Hospital admission was only reported in one study [14]; 
showing higher hospital admission rates in contacts of 
vaccinated persons (OR: 1.92; 95% CI: 1.17–3.14). There 
were no studies reporting on mortality endpoints.
Risk of bias and grading of evidence
The most common potential risks of bias in the included 
RCTs were lack of appropriate generation of the ran-
domisation sequence, lack of allocation concealment 
and lack of blinding of patients and healthcare provid-
ers (Table 2). The RCTs scored a mean of 4.3 (range: 
2–7) when assessed against seven domains. 
The observational studies were awarded a mean of 
6.25 points of a maximum of nine on the Newcastle-
Ottawa scale, i.e. they were in a middle range of risk of 
bias (7 for Piedra et al. [26] and Ghendon et al. [25], 6 
for Kjos [27] and 5 for King et al. [14]).
Applying GRADE criteria, we decreased the level of 
evidence for the primary outcome because of serious 
limitations in the quality of the studies (i.e. risk of bias 
in RCTs and observational design in non-RCTs) and 
inconsistency with significant statistical heterogene-
ity. Therefore, the overall level of evidence support-
ing a herd effect of influenza vaccines in preventing 
Table 2
Risk of bias in nine included randomised controlled trials reporting on influenza infections in contacts of influenza 
vaccinated vs unvaccinated individuals in non-healthcare settings
First author 
[source]
Risk of bias
Sequence 
generation
Allocation 
concealment
Blinding of 
patients
Blinding of 
healthcare provider
Blinding of outcome 
adjudicators
Incomplete data 
addressed
Selective 
reporting
Gruber [29] NK NK Low Low Low Low Low
Clover [33] NK NK Low NK Low Low Low
Rudenko [23] NK NK Low NK Low Low Low
Hurwitz [13] NK NK Low NK NK NK Low
Esposito [34] Low NK Low Low Low Low Low
Principi [24] NK NK High High NK Low Low
Hui [31] NK NK High High Low Low Low
Cowling [30] Low NK  Low Low Low Low Low
Loeb [12] Low Low Low Low Low Low Low
Percentage low 
risk of biasa 33 11 22 33 78 89 100
NK: not known, as either unclear or not reported.
a The percentage low risk of bias for each domain was calculated by dividing the number of randomised controlled trials (RCTs) at low risk of 
bias by the total number of RCTs (n = 9).
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influenza virus infection in contacts in non-healthcare 
settings was considered to be low.
Discussion
We found an overall low level of evidence supporting an 
indirect or herd effect of influenza vaccination in pre-
venting influenza virus infection in vaccinated persons’ 
contacts. In all but one study we identified, children 
were vaccinated. While observational studies showed 
a significant effect, the summary estimates from RCTs 
did not show a statistically significant effect. Few data 
were available on herd effect of influenza vaccination 
preventing hospital admission, pneumonia and death.
Point estimates of four of the six RCTs that reported on 
the prevention of influenza virus infection in contacts 
of vaccinated persons pointed towards a potential ben-
efit of vaccination, but no significant effect was found 
overall. In an RCT by Loeb et al. involving Hutterite com-
munities [12], vaccination of children in an enclosed 
community significantly reduced influenza infections 
in contacts. The uptake of influenza vaccination in 
that RCT, which had a low risk of bias in all domains 
assessed, was ca 83%. The RCT confirmed the findings 
from an observational study by Monto et al. that found 
a similar effect at the population level by vaccinating 
schoolchildren in one community in Michigan, United 
States [28]. However, no strong evidence was found in 
a household setting [29,30]. A possible explanation is 
that vaccinating only one child per household, as done 
in the study by Cowling et al., may have been insuffi-
cient to have a measurable effect [30]. In the study by 
Gruber et al., in contrast, all children three years of age 
and older received the vaccine, but again there was 
no effect on household contacts. However, the study 
was limited by the low attack rate and was therefore 
likely underpowered [29]. Furthermore, the authors 
argued that the non-vaccinated contacts were likely to 
be immune to the predominant influenza B strain that 
circulated in previous years. It is therefore unclear what 
key factors are needed to achieve a herd effect in the 
household, particularly given the importance of the 
broader community as a potential source of infection of 
the non-vaccinated. Notably, the only study that inves-
tigated herd effect of influenza vaccination of adults 
did find a statistically significant effect [31]. However, 
this study had significant methodological limitations, 
including lack of blinding. It should be acknowledged 
that two studies that both reported a significant herd 
effect of influenza vaccination could not be included in 
the meta-analysis because of the lack of detail reported 
in the published article, and no additional information 
could be obtained from the authors [23,24]. 
In contrast to our findings from RCTs, we found evi-
dence of herd effect following influenza vaccination 
in observational studies, which was corroborated by 
a recent observational study by Pannaraj et al., who 
found that unvaccinated children may be protected in 
schools with vaccination rates approaching 50% [32].
Our extensive screening of over 40,000 studies found 
very few studies that were designed to measure herd 
effects of influenza vaccination. One reason for this 
may be the cost of community influenza surveillance as 
well as the cost of clinical trials. While modelling stud-
ies demonstrate that herd immunity can be achieved 
by vaccinating young children [10], we are surprised 
by how few studies with laboratory-confirmed influ-
enza as an outcome support the modelling literature. 
Moreover, there are very limited data available to esti-
mate herd effect of influenza vaccination programmes. 
As indirect benefits would increase the cost-effective-
ness of these programmes, such data would be highly 
valuable for vaccine advisory bodies and decision mak-
ers evaluating whether to initiate or expand influenza 
vaccine programmes.
Our review highlights the need for more rigorous 
studies using laboratory-confirmed influenza virus 
infections as an outcome. Data on a herd effect on 
outcomes other than influenza virus infection were 
sparse, due either to outcomes not being measured or 
to inadequate power to detect a difference. Although 
the effect of influenza vaccination on mortality has 
been demonstrated through modelling [10], high-qual-
ity studies would better support the ability of influenza 
vaccination to prevent hospital admissions, pneumonia 
or death in contacts through herd effect.
Strengths of this systematic review include a system-
atic, protocol-driven and comprehensive review with 
extensive literature search strategy including RCTs and 
observational studies. In addition, rigorous assess-
ment of eligibility ensured high reliability of the results. 
All subgroup analyses were defined a priori. A rigorous 
use of the GRADE approach ensured a transparent and 
comprehensive approach to evaluate overall quality of 
the studies. An important limitation, however, was the 
presence of statistically significant heterogeneity that 
could not be explained by a priori defined subgroup 
analyses. We assume that differences in study designs 
and clinical heterogeneity in terms of study population, 
outcome assessment and health service resources may 
have resulted in differences in outcomes that could not 
be explained by the intervention per se. Furthermore, 
differences in vaccine effectiveness in case of mis-
match and existing immunity if the circulating strain 
had been dominant for several seasons may have 
introduced heterogeneity across the included studies. 
Another major limitation was the potential risk of bias 
in the majority of studies, which further decreased the 
level of evidence. Finally, all but one study vaccinated 
children, thus, no generalisation to vaccination pro-
grammes in adults can be made, and the evidence is 
too limited to conclude in what setting(s) a significant 
herd effect may or may not be achieved.
In summary, herd effects are assumed with influenza 
vaccine programmes, but there are few studies that 
quantify the herd effect of vaccination. We found low-
level evidence supporting a herd effect of vaccination 
8 www.eurosurveillance.org
on influenza virus infection in contacts of vaccinated 
persons. Further rigorous studies are needed in order 
to better understand under which circumstances vac-
cination may prevent influenza and its complications in 
contacts.
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